lu 135252 has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amann, K; El-Shakmak, A; Gross, ML; Hansen, A; Heiss, N; Münter, K; Ritz, E; Szabo, A; Weckbach, M | 1 |
2 other study(ies) available for lu 135252 and Cardiovascular Diseases
| Article | Year |
|---|---|
ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Arterioles; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Collagen Type IV; Coronary Vessels; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Endothelin-1; Fibrosis; Gene Expression; Heart; Immunohistochemistry; In Situ Hybridization; Indoles; Male; Myocardium; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Transforming Growth Factor beta | 2004 |
LU 135252. HMR 4005.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Drugs, Investigational; Endothelin Receptor Antagonists; Phenylpropionates; Pyrimidines; Receptor, Endothelin A | 1999 |